Clinical trial NCT00607672: The RAS, Fibrinolysis and Cardiopulmonary Bypass
Official title: The RAS, Fibrinolysis and Cardiopulmonary Bypass
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Coronary Artery Disease
Angiotensin Converting Enzyme
Angiotensin Receptor Blockers
Cardiopulmonary Bypass
Fibrinolysis
Inflammation
Keywords: Angiotensin Converting Enzyme
Angiotensin Receptor Blockers
Cardiopulmonary Bypass
Fibrinolysis
Inflammation
Lead sponsor: Vanderbilt University
Sponsor class: OTHER
First posted: 2008-02-06
Enrollment: 111
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Each year over a million patients worldwide undergo cardiac surgery requiring cardiopulmonary bypass (CPB).1 CPB is associated with significant morbidity including hemodynamic instability, the transfusion of allogenic blood products, and inflammation. Blood product transfusion increases mortality after cardiac surgery. Enhanced fibrinolysis contributes to increased blood product transfusion requirements in the perioperative period. CPB activates the kallikrein-kinin system (KKS), leading to increased bradykinin concentrations. Bradykinin, acting through its B2 receptor, stimulates the release of nitric oxide, inflammatory cytokines and tissue-type plasminogen activator (t-PA). Based on data indicating that angiotensin-converting enzyme (ACE) inhibitors reduce mortality in patients with coronary artery disease, many patients undergoing CPB are taking ACE inhibitors. While interruption of the renin-angiotensin system (RAS) reduces inflammation in response to CPB, ACE inhibitors also potentiate the effects of bradykinin and may augment B2-mediated change in fibrinolytic balance and inflammation. In contrast, angiotensin II type 1 receptor antagonism does not potentiate bradykinin and does not inhibit bradykinin metabolism.

Studies in animals suggest that bradykinin receptor antagonism inhibits reperfusion-induced increases in vascular permeability and neutrophil recruitment.A randomized, placebo controlled clinical trial of a bradykinin B2 receptor antagonist demonstrated some effect on survival in patients with systemic inflammatory response syndrome and gram-negative sepsis. In addition, we and others have shown bradykinin B2 receptor antagonism reduces vascular t-PA release during ACE inhibition. The current proposal derives from data from our laboratory and others elucidating the role of the KKS in the inflammatory, hypotensive and fibrinolytic response to CPB. Specifically, we have found that CPB activates the KKS and that ACE inhibition and smoking further increases bradykinin concentrations. During CPB, bradykinin concentrations correlate inversely with mean arterial pressure and directly with t-PA. Moreover, we have found that bradykinin receptor antagonism attenuates protamine-related hypotension following CPB. The current proposal tests the central hypothesis that the fibrinolytic and inflammatory response to cardiopulmonary bypass differ during angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism.


Eligibility criteria: Inclusion Criteria:

Inclusion Criteria

1. Subjects, 18 to 80 years of age, scheduled for elective cardiac surgery requiring CPB
2. For female subjects, the following conditions must be met:

postmenopausal for at least 1 year, or status-post surgical sterilization, or if of childbearing potential, utilizing adequate birth control and willing to undergo urine beta-hcg testing prior to drug treatment and on every study day

Exclusion Criteria:

1. Left ventricle ejection fraction less than 30%
2. History of ACE inhibitor-induced angioedema
3. Hypotension (systolic blood pressure \<100 mmHg and evidence of hypoperfusion)
4. Hyperkalemia (baseline potassium \>5.0 mEq/L)
5. Inability to discontinue current ACE inhibitor or AT1 receptor antagonist.
6. Emergency surgery
7. Impaired renal function (serum creatinine \>1.6 mg/dl)
8. Pregnancy
9. Breast-feeding
10. Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult
11. History of alcohol or drug abuse
12. Treatment with any investigational drug in the 1 month preceding the study
13. Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study
14. Inability to comply with the protocol, e.g. uncooperative attitude and unlikelihood of completing the study

Primary outcomes:
measure: Tissue-type Plasminogen Activator (t-PA) Antigen Response
timeFrame: From the start of surgery until postoperative day 2
measure: Plasminogen Activator Inhibitor-1 (PAI-1) Response
timeFrame: From the start of surgery until postoperative day 2
measure: Interleukin-6 (IL-6) Response
timeFrame: From the start of surgery until postoperative day 2
measure: Interleukin-8 (IL-8) Response
timeFrame: From the start of surgery until postoperative day 2
measure: Interleukin-10 (IL-10) Response
timeFrame: From the start of surgery until postoperative day 2
Secondary outcomes:
measure: Blood Loss
timeFrame: First 24 hours after arrival in the intensive care unit
measure: Re-exploration for Bleeding
timeFrame: From arrival in intensive care unit until discharge from hospital
measure: Blood Product Transfusion Requirement
timeFrame: From the start of surgery until discharge from hospital
measure: Vasopressor Drug Use
timeFrame: From the end of cardiopulmonary bypass until arrival in intensive care unit
measure: New Onset Atrial Fibrillation
timeFrame: From arrival in intensive care unit until discharge from hospital
measure: Acute Kidney Injury
timeFrame: From the start of surgery until postoperative day 3
measure: Stroke
timeFrame: From arrival in intensive care unit until discharge from hospital
measure: Length of Hospital Stay
timeFrame: From the start of surgery until discharge from hospital
Other outcomes:
Locations:
city: Nashville
country: United States
facility: TN Valley Healthcare System
state: Tennessee
city: Nashville
country: United States
facility: Vanderbilt University
state: Tennessee
Study officials:
affiliation: Vanderbilt University
name: Mias Pretorius, MBChB, MSc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Billings FT 4th, Balaguer JM, C Y, Wright P, Petracek MR, Byrne JG, Brown NJ, Pretorius M. Comparative effects of angiotensin receptor blockade and ACE inhibition on the fibrinolytic and inflammatory responses to cardiopulmonary bypass. Clin Pharmacol Ther. 2012 Jun;91(6):1065-73. doi: 10.1038/clpt.2011.356.
citation: Gamboa JL, Pretorius M, Sprinkel KC, Brown NJ, Ikizler TA. Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study. BMC Nephrol. 2015 Oct 22;16:167. doi: 10.1186/s12882-015-0162-x.